The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.
Biota Pharmaceuticals Office Locations
Biota Pharmaceuticals Data and Metrics
Biota Pharmaceuticals Financial Metrics
Revenue (Q3, 2017) | 4.9 m |
Net income (Q3, 2017) | (4.4 m) |
EBIT (Q3, 2017) | (3.8 m) |
Cash (31-Mar-2017) | 11.8 m |
- Source: SEC Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 68.7 m | 24.6 m | 9.3 m |
Revenue growth, % | (64%) | (62%) | |
Cost of goods sold | 51.1 m | 3.6 m | |
Gross profit | 17.6 m | 21 m | |
Gross profit Margin, % | 26% | 85% | |
R&D expense | 26.3 m | ||
General and administrative expense | 8 m | ||
Operating expense total | 80.2 m | 44.1 m | 34.5 m |
EBIT | (11.5 m) | (19.5 m) | (25.2 m) |
EBIT margin, % | (17%) | (79%) | (271%) |
Net Income | (11 m) | (19.1 m) | (25.4 m) |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 700 k | 13.9 m | 5.9 m | 1.7 m | 1.7 m | 5.3 m | 100 k | 3.8 m | 4.9 m |
Cost of goods sold | 1.7 m | 1.6 m | 300 k | ||||||
Gross profit | (1 m) | 12.3 m | 5.6 m | ||||||
Gross profit Margin, % | (143%) | 88% | 95% | ||||||
R&D expense | 4.9 m | 4.8 m | 4.8 m | 5.5 m | 6.3 m | 8.5 m | 7.6 m | 10.2 m | 6.8 m |
General and administrative expense | 2.4 m | 2.6 m | 3.2 m | 2.2 m | 2.1 m | 2.3 m | 2.2 m | 2.1 m | 1.8 m |
Operating expense total | 7.3 m | 7.4 m | 8 m | 7.7 m | 8.4 m | 10.8 m | 9.8 m | 12.3 m | 8.6 m |
EBIT | (7 m) | 6.4 m | 1.1 m | (6.7 m) | (6.5 m) | (5.2 m) | (9.6 m) | (8.6 m) | (3.8 m) |
EBIT margin, % | (1000%) | 46% | 19% | (394%) | (382%) | (98%) | (9600%) | (226%) | (78%) |
Interest income | 100 k | 100 k | 100 k | 100 k | 100 k | 100 k | |||
Pre tax profit | (6.6 m) | ||||||||
Income tax expense | 100 k | 200 k | |||||||
Net Income | (6.9 m) | 6.5 m | 1.2 m | (6.6 m) | (6.5 m) | (5.2 m) | (10 m) | (9.1 m) | (4.4 m) |
- Source: SEC Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 81.7 m | 44.7 m | 49.7 m |
Current Assets | 101.1 m | 70.8 m | 72.4 m |
PP&E | 2 m | 200 k | 300 k |
Total Assets | 114 m | 79.4 m | 72.7 m |
Accounts Payable | 2.8 m | 1.9 m | 3.9 m |
Current Liabilities | 26.9 m | 9 m | 9.2 m |
Total Liabilities | 26.5 m | ||
Additional Paid-in Capital | 146.4 m | 155.6 m | 157.6 m |
Retained Earnings | (89.8 m) | (108.9 m) | (134.3 m) |
Total Equity | 86.9 m | 69.5 m | 46.2 m |
Financial Leverage | 1.3 x | 1.1 x | 1.6 x |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 57.7 m | 63.7 m | 61.5 m | 45.3 m | 39 m | 30.6 m | 45.9 m | 38.1 m | 11.8 m |
Accounts Receivable | 10.1 m | 3.2 m | |||||||
Current Assets | 76.1 m | 86.2 m | 87.4 m | 61.2 m | 58.6 m | 60.5 m | 62.8 m | 56.2 m | 46.4 m |
PP&E | 1.6 m | 1.1 m | 300 k | 200 k | 400 k | 400 k | 300 k | 300 k | 300 k |
Total Assets | 97.3 m | 93.4 m | 88.8 m | 71 m | 64.2 m | 61.9 m | 63.1 m | 56.5 m | 46.7 m |
Accounts Payable | 1.4 m | 1.7 m | 1 m | 2.9 m | 1.3 m | 3.7 m | 1.6 m | 3.4 m | 1.8 m |
Current Liabilities | 19.3 m | 10.9 m | 7.2 m | 6.7 m | 6 m | 8.7 m | 8.8 m | 10.5 m | 5.5 m |
Additional Paid-in Capital | 146.8 m | 147.4 m | 148 m | 156.2 m | 156.8 m | 157.2 m | 158 m | 158.5 m | 159.1 m |
Retained Earnings | (96.7 m) | (90.2 m) | (89 m) | (115.5 m) | (122.1 m) | (127.3 m) | (144.3 m) | (153.4 m) | (157.8 m) |
Total Equity | 63.5 m | 57.5 m | 52.7 m | 36.6 m | 28 m | 24.2 m | |||
Financial Leverage | 1.1 x | 1.1 x | 1.2 x | 1.7 x | 2 x | 1.9 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | (11 m) | (19.1 m) | (25.4 m) |
Depreciation and Amortization | 2.4 m | 1.1 m | 100 k |
Accounts Receivable | (7.1 m) | 6.2 m | 11.9 m |
Cash From Operating Activities | (3.3 m) | (9.6 m) | (14.1 m) |
Purchases of PP&E | (100 k) | (100 k) | (200 k) |
Cash From Investing Activities | (10.1 m) | (19.4 m) | 1.3 m |
Cash From Financing Activities | 26.8 m | (100 k) | 17.8 m |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (6.9 m) | 6.5 m | 1.2 m | (6.6 m) | (6.5 m) | (5.2 m) | (10 m) | (9.1 m) | (4.4 m) |
Accounts Receivable | 10.1 m | 3.2 m | |||||||
Accounts Payable | 1.4 m | 1.7 m | 1 m | 2.9 m | 1.3 m | 3.7 m | 1.6 m | 3.4 m | 1.8 m |
| Y, 2017 | |
|---|---|
Financial Leverage | 1.9 x |
